Michael T. Nally has served on the PPG board since 2021 and is Chief Executive Officer and a director of Generate Biomedicines, Inc. and a CEO-partner of Flagship Pioneering.
His leadership experience in the pharmaceutical industry and with the use of artificial intelligence brings extensive understanding of the research and development process and the importance of product innovation to growth. At Merck he was responsible for developing the company's growth strategy and commercialization model, and he has valuable experience commercializing new technologies, marketing products to consumers and managing significant global businesses.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.